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ABSTRACT
TARGETING FAS PATHWAY AS AN EFFECTIVE MEANS OF INDUCING
TOLERANCE TO PANCREATIC ISLETS
Kyle Woodward
August 8, 2017
Signaling through Fas/FasL is critical to immune homeostasis and
tolerance to self-antigens. SA-FasL is a chimeric protein of FasL and
streptavidin. SA-FasL exists as oligomers with potent apoptotic function on Fas
expressing immune cells and tightly binds to biotinylated surfaces. Islet grafts
engineered to transiently display SA-FasL on their surface established tolerance
in allogeneic recipients with a short course of rapamycin.
We hypothesized that SA-FasL on the islet allograft will induce apoptosis
in alloreactive T effector (Teff) cells and phagocytes clearing apoptotic bodies will
produce tolerogenic molecules, such as TGF-β, that will lead to the generation
and/or expansion of Treg cells at the induction phase. Treg cells will then home
to allografts in response to inflammatory cues and will be maintained in the graft
by alloantigens for long-term graft protection. In support of this hypothesis, we
demonstrated reduced alloreactive T cells in the draining lymph nodes of SAFasL-engineered grafts as compared to controls. Depletion of phagocytes or
blocking TGF-β peri- and immediate post-transplantation of allogeneic SA-FasLislet grafts abrogated tolerance as the grafts were rejected acutely.

v

Systemic nature of the tolerance at the induction phase was shown by
demonstrating that both un-engineered as well as SA-FasL-engineered islet
grafts simultaneously transplanted under the contralateral kidney capsules
survived indefinitely. SA-FasL-islets had characteristics of immune privilege as
chemical destruction of the long-term graft followed by the transplantation of an
un-engineered graft at the same location 4 days later resulted in the protection of
the second set graft.
We also tested whether tolerance to allografts requires physical presence
of SA-FasL on the graft. To investigate this, we engineered biotinylated poly
ethylene glycol (PEG) hydrogel or poly(lactic-co-glycolide) (PLGA) scaffolds with
SA-FasL and co-transplanted with unmanipulated allogeneic islets under the
kidney capsule or epididymal fat pad, respectively, resulted in indefinite ( > 200
days) islet survival. Flow cytometry revealed increased amounts of Tregs in the
graft and draining lymph nodes in the PEG model. Mice rejected these grafts
when Tregs were depleted. Taken together, the studies presented herein
elucidate the mechanistic basis of SA-FasL-mediated tolerance and show that
SA-FasL-engineered biomaterials are also effective in inducing tolerance.
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CHAPTER 1: INTRODUCTION

Type 1 diabetes
Diabetes affects a rapidly increasing number of people each year. In 2014,
29 million people in the United States alone suffered from diabetes1. It
contributes to 200,000 deaths and is estimated to cost $245 billion in the US per
year1. A significant portion (5-10%) of those with diabetes in the US are afflicted
with the autoimmune form known as type 1 diabetes. Diabetes is characterized
by hyperglycemia and can contribute to hypertension, blindness, kidney disease,
and the need for limb amputations.
Type 1 diabetes is caused by the loss of insulin producing β cells in the
islets of Langerhans, located in the pancreas. Genetics play a large role in the
onset of type 1 diabetes, as several genes have been linked to increased
susceptibility. Among the strongest correlations with the disease are MHC
genes2, 3. Further adding to the evidence for the genetic basis of diabetes, in
studies examining monozygotic twins where one has type 1 diabetes the second
twin was diabetic in approximately 50% of the pairs of twins in the study4, 5.
However, as the concordance rate of type 1 diabetes among monozygotic
twins is only around 50%, environmental factors are implicated as another
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contributor to the development of disease. Although the nature and diversity of
the environmental factors yet to be fully investigated, viruses are considered one
of the main suspects. Coxsackie virus may initiate inflammation and β cell
antigen shedding leading to type 1 diabetes, as it has been shown to infect
human β cells in vitro and infection was inhibited by type I and type II
interferons6. Viral infections can then increase the MHC I expression on the
surface of β cells, and also lead to the production of inflammatory cytokines,
which lead T cells and other leukocytes to attack infected β cells and possibly
uninfected β cells as well7. As Non-obese diabetic (NOD) mice spontaneously
become diabetic, these mice have been used to study many facets of
autoimmune diabetes, which may have parallels to T1D in humans. NOD mice
with suppressor of cytokine signaling 1 knocked out (SOCS-1-Tg NOD) become
diabetic after infection with Coxsackie virus, further implicating it as a possible
trigger for the cascade of events which ultimately leads to T1D6.
Later events in that cascade are more studied, as early signs of diabetes
can be detected once β cell loss is significant enough. In recently deceased
human patients suffering from T1D, CD8+ and CD4+ T cells, macrophages, and
CD20+ B cells are found infiltrating islets in higher levels when compared to nondiabetics8. On top of that, T cells are suspected to play a large role due to
genetic screening revealing that HLA genes show the strongest link to T1D in
humans, with DR3/4-DQ8 comprising almost 50% of children with anti-islet
autoimmunity by the age of 53, implying that CD4+ T cells in these patients may
play a key role in the destruction of β cells. In NOD mice, CD4 + T cell depletion
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reverses new onset diabetes, further adding weight to the idea that they are a
crucial cell type in the development of T1D9. Furthermore, proinsulin and insulin
are major targets of CD4+ T cells and mice transgenic for proinsulin that was
modified to eliminate a dominant CD4+ T cell epitope do not develop T1D10.
CD8+ T cells may have a huge part in β cell destruction as well, as evidenced by
a study showing HLA-A2+ patients have circulating CD8+ T cells that kill β cells in
vitro by targeting a pre-proinsulin peptide chain2. This observation is also
supported by mouse studies, as CD8+ T cells in NOD mice have been discovered
which recognize the insulin β chain, and can therefore target β cells11. See
Figure 1 for a schematic diagram of the events leading to islet destruction.

Treatment of type 1 diabetes
One of the miracles of modern medicine is the availability of insulin to treat
diabetes. However, even with insulin administration blood glucose is often
difficult to regulate, and thus the severe of long-term effects such as kidney
disease and arterial damage leading to limb amputation may still occur with such
treatment.
Another option being explored is the prevention of diabetes through early
screening and immunosuppression. Genetically at risk children can be positively
screened for insulin autoantibodies and islet cell antibodies long before beta cell
destruction is complete12.

Additionally, when type 1 diabetes is initially

diagnosed, there is often a honeymoon period in which administration of insulin
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eases the burden of the few remaining beta cells allowing them to produce
insulin. If the autoimmune aspects of type 1 diabetes were regulated at these
points, possibly through T cell suppression, diabetes could theoretically be
reversed when the patients recover beta cells and therefore regain sufficient
control of blood glucose levels. However, genetic and antibody screening of all
children is not yet practical, and no studies have sufficiently prevented diabetes
as of yet. For instance, studies with vaccination soon after diagnosis using alum
and glutamic acid decarboxylase, a critical protein in autoimmune diabetes,
found no significant reduction in insulin production loss among other factors, in
direct contrast to animal models which show vaccination to a target antigen to be
tolerizing13, 14. Therefore, I do not see this as an alternative to transplantation, but
rather a potential treatment option.
A fourth option for treatment of type 1 diabetes is transplanting of beta cell
containing islets from healthy donor pancreas. Successful transplantation of
islets is an effective cure of T1D, and working out protocols which allow the
patient to retain the transplant are therefore currently a focus in T1D research.
The current leading clinical protocol, the Edmonton Protocol, is able to restore
control of blood glucose through intraportal transplant of islets

15

. Despite the

great success of the Edmonton Protocol, it is still far from an ultimate solution to
type 1 diabetes.

Upon following the patients, only 31% retained insulin

independence after two years, and 10% after five years15, 16.
Islet transplants under this protocol are done by injecting islet cells directly
into the portal vein. This is very convenient, bypassing the need for surgery, and
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as islets are in contact with the blood stream they may easily detect blood
glucose levels and secrete insulin into the blood in response. However, such
direct injection into the portal vein leads to the instant blood mediated
inflammatory reaction, in which a large amount of islets are swiftly destroyed 17, 18.
This is characterized by platelets binding the islets, coagulation, infiltration of
CD11b+ cells, compliment activation, and destruction of the islets17.
In order to compensate for the islets to this instant blood mediated
inflammatory reaction, more islets must be transplanted in the beginning. This
may require up to four donors to have islets pooled together in order to gain
successful insulin independence19. This may be somewhat obviated by
transplanting islets in another location, however, no suitable replacements for
intraportal transplantation have been sufficiently researched for clinical islet
transplants as of yet.
In addition to the immediate loss of islets due to instant blood mediated
inflammatory reaction, there is a slower loss due to the immune response. Under
the Edmonton Protocol, multiple donors are required for a single transplant,
giving a large chance that one or more of the sets of donated islets will not be
HLA matched. As with many mismatched transplants, effector T cells can soon
destroy the graft without proper immunosuppressive drugs. Those used in this
protocol are daclizumab, rapamycin, and tacrolimus. Daclizumab is an IL-2
receptor monoclonal antibody which inhibits IL-2 uptake in effector T cells,
blocking proliferation and growth. This also blocks IL-2R on regulatory Tregs, and
therefore may have conflicting effects. Rapamycin, also known as sirolimus,
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works through inhibition of mTOR, which in turn inhibits effector T cells and is
known to induce regulatory T cells in vitro. Tacrolimus is a calcineurin inhibitor
that blocks IL-2 production in T cells. Altogether, these drugs are effective at
stopping much of the T cell response that would quickly eliminate transplanted
islets. However, increasing evidence shows that long-term use of tacrolimus and
rapamycin as per the Edmonton Protocol causes damage to kidneys and islets,
suggesting that these drugs may be counterproductive20,

21

. In addition, such

immunosuppression weakens the body’s natural defense against tumors and
infections.

Immune regulation as an approach to induce allotolerance
Despite their toxic effects, these drugs must be used under the current
protocol in order to keep T cell mediated rejection under control. In addition,
autoreactive CD8+ and CD4+ T cells have already established β-cell
autoimmunity in T1D patients. As such, how can effector T cells be kept in
check? There are several methods already existing in the immune system to stop
or control rogue T cells, including the deletion of T cells in the thymus, known as
central tolerance. This is brought about by APCs such as medullary thymic
epithelial cells or dendritic cells in the thymus presenting antigen to T cells in the
thymus22. T cells that tightly bind to self-antigens presented by MHC class I or
class II are deleted before being allowed to escape to the periphery and cause
damage.
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While this system has been extensively studied as a preemptory
mechanism to control autoimmunity, its validity has also been shown in
transplant settings. In a rat allogeneic islet transplant model, Posselt et al.
showed that allogeneic islets transplanted into the thymus survived indefinitely
through deletion of alloreactive T cells23. This central tolerance translated into
systemic tolerance, as a second set of donor-matched islets transplanted under
the kidney capsule of the thymically manipulated rats also survived without
further immune intervention.
Relevant to the context of this thesis are studies with bone marrow mixed
chimerism to induce tolerance. Mixed chimeras were shown to be tolerant to
both the donor and recipient antigens established by thymic deletion of
responding T cell clones24. The presence of a functional Fas ligand protein
(FasL, CD95L) on the surface of donor bone marrow cells was shown to be
requisite for the induced tolerance25, 26.

Tregs as a mediator of tolerance
Immune tolerance to self-antigens is maintained not only by central
tolerance through the deletion of autoreactive T cells in the thymus, but also by
several peripheral mechanisms. CD4+CD25+Foxp3+ regulatory cells (Tregs) are
critical to peripheral tolerance mechanisms27 as the lack of these cells or defects
in their function results in massive autoimmunity in humans and rodents 28,

29

.

Tregs are either developed in the thymus (tTregs) or induced in the periphery
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(pTreg). Tregs express several markers which aid in their suppressive function,
including CTLA-4, ICOS, and LAG-330 and suppress not only T effector cells, but
various other immune effector cells, such as NK cells, B cells. Tregs suppress
target cells through cell-to-cell contact as well as various immunosuppressive
cytokines, such as IL-10 and TGF-β, or through competition for IL-2, a cytokine
required for the generation, expansion, and function of Tregs31.
Importantly, Tregs have been shown to suppress autoimmune diabetes in
the BDC2.5/NOD mouse model32.

These mice are genetically modified to

contain a CD4+ T cell population which is specific for β cell antigen, however they
are kept in check by regulatory cells, blocking the onset of diabetes in young
BDC2.5/NOD mice. When Tregs in 5-week-old BDC2.5/NOD mice are depleted
through diphtheria toxin receptor expressed under the control of FOXP3
promotor, and therefore, Treg specific, they acquired overt diabetes in 3-5 days
32

. Humans with recent onset of T1D were shown to have normal frequency of

Treg cells, yet they have a reduced ability to suppress effector T cell proliferation
in vitro33. Ex vivo expanded Treg cells were shown to prevent and reverse TD in
NOD and the expanded cells have been tested in various clinical trials to prevent
treat T1D as well as prevent allograft rejection with reported clinical benefits 34, 35.
Important in the context of this dissertation are our published observations
that CD4+CD25+Foxp3+ regulatory cells are critical to tolerance established by
pancreatic islets engineered with SA-FasL27. Confocal microscopy revealed an
increased number of Tregs located in the long-term allogeneic islet grafts. Tregs
were critical not only for the induction, but also maintenance of tolerance.
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Depletion of Tregs with an antibody to CD25 early post-transplantation (day 14)
or after long-term tolerance had been established (day 100) resulted in rejection
of islet grafts in both groups of mice. The exact mechanisms by which Tregs are
generated by SA-FasL and if they are thymic or induced are yet to be elucidated.
SA-FasL may shift the balance of Teffs/Tregs in favor of Tregs by selectively
inducing apoptosis in Teffs. Consistent with this notion, studies demonstrating
that Tregs are more resistant to Fas/FasL mediated apoptosis due to their
increased expression of c-FLIP36 and SA-FasL-engineered Tregs have better
regulatory function than the unmanipulated cells in preventing T1D and graft-vshost diseases in preclinical models37, 38.

Rapamycin in transplantation
Another pathway to increase Tregs is through TGF-β and rapamycin. In
vitro, it has been shown that a combination of TGF-β and rapamycin converts
conventional T cells into Tregs39. These converted Tregs are known as induced
Tregs (iTregs) if developed in vitro or peripheral Tregs (pTregs) if developed in
vivo. Such peripherally generated Tregs are necessary to control autoimmunity,
as not all T cells that are able to respond to self-antigen are deleted in the
thymus. iTregs have suppressive activity and can be identified by the lack of
Helios or Nrp-1 40.
Rapamycin also increases the Treg to Teff ratio through suppressing the
growth of effector T cells, and expanding Tregs41.
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Rapamycin functions by

inhibiting mammalian target of rapamycin (mTOR)42. Deletion of mTOR in mice T
cells causes them to spontaneously become iTregs43. Rapamycin is currently in
use as an immunosuppressive drug in the Edmonton Protocol, one of the leading
protocols on islet transplantation44. However, in current use, it must be
administered long-term in order to stave off rejection. During such long-term use,
rapamycin is toxic to β-cells, reducing their insulin secretion, mass, and
proliferation, while increasing their autophagy and apoptosis45, 46. Therefore, the
time of rapamycin administration must be shortened drastically or eliminated in
order for a favorable outcome in the cure of diabetes.
Other methods of increasing the Treg:Teff cell ratio include IFN-γ and
indoleamine 2,3-dioxygenase (IDO)47. Despite the fact that it is thought of as an
inflammatory cytokine, sustained IFN-γ activity can be tolerogenic. IFN-γ has
been shown to activate IDO production in DCs48. IDO is an enzyme that
catalyzes the degradation of tryptophan, and as such may starve T cells and
prevent their activation and proliferation. IDO also has been shown to induce
CD4+ T cells to become regulatory T cells. The observed synergy between SAFasL and rapamycin may operate through DC expression of IDO in response to
rapamycin and IDO initiating a forward regulatory loop resulting in the generation
of Tregs47. Rapamycin has also been shown to work in conjunction with another
anti-inflammitory cytokine, IL-1049.

This combination of treatment induces T

regulatory type one (Tr1) cells which have proven to aid in tolerance in islet
transplantation49.
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Rapamycin also affects B cell proliferation50. It blocks entry into the S
phase of cell growth in B cells, and inhibits differentiation into plasma cells50. As
a result, less anti-donor antibodies are generated. This three pronged tolerance
induction through inhibition of B and T cell responses and the increase in Treg
responses make rapamycin an ideal immunomodulatory drug.

Fas-mediated activation induced cell death (AICD) as a means of
immunomodulation
Fas is expressed in the thymus, heart, and liver51, and notably on the surface of
activated B and T cells. FasL is found on the surface of activated T cells and NK
cells, as well as in immune privilege sites such as testis and eye 52. The
interaction of Fas with FasL is a critical mechanism of immune homeostasis and
self-tolerance through activation-induced cell death (AICD). Mutations in affecting
the function of Fas or FasL result in hyper proliferation of lymphocytes and
autoimmunity, suggesting that the Fas pathway has a non-redundant function
vital to immunoregulation53,

54

. Fas pathway was also shown to be important to

immune privilege status of various organs, such as eyes and testicular tissues55.
Fas/FasL-interaction was also demonstrated to be involved in acquired tolerance
to tumors. Many tumors express FasL as a mechanism of immune evasion by
inducing apoptosis in T effector cells responding to tumor associated antigens56.
As such, the Fas pathway has great potential to regulate immune response and
has been the subject of intense research.
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In addition to naïve T cells becoming activated in response to encounters
with donor cells, humans and nonhuman primates have preexisting memory T
cells from previous infections which can also cross-react with transplants, known
as heterologous immunity57,
primates express Fas59,

58

. These memory cells in humans and nonhuman

60

. In addition, both CD8+ and CD4+ memory cells are

sensitive to Fas/FasL mediated apoptosis61, 62.
In researching just how fundamental apoptosis is to inducing peripheral
tolerance, Li et al. found that blocking apoptosis with cyclosporin A inhibits
allograft tolerance even with costimulatory blockade 63. However, attempts to
harness the power of Fas/FasL in order to cause apoptosis of donor reactive T
cells have met with mixed results. Use of an agonistic Fas antibody in mice
induced apoptosis, but had the side effects of liver toxicity and death, presumably
because of the expression of Fas on liver tissue64.
In utilizing gene therapy to manipulate apoptosis of donor reactive T cells,
FasL overexpression on heart grafts surprisingly accelerated rejection with a
massive increase in neutrophil infiltration into the graft65. Upon further study, it
was found that FasL is cleaved from the membrane through matrix
metalloproteinases

66, 67

, and that chemotaxis of neutrophils is activated by the

soluble form of FasL, and not the membrane bound form68,

69

. In addition,

membrane bound FasL is effective at inducing apoptosis, but soluble FasL
actually blocks apoptosis in T cells70. Therefore, the use of FasL as an effective
immune regulatory will require separation of its apoptotic function from
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chemotactic and anti-apoptotic functions. See Figure 2 for a schematic diagram
of Fas/FasL induced apoptosis.
SA-FasL as a novel form of FasL
In order to combat these problems in inducing tolerance to transplants,
Yolcu et al. generated a novel form of FasL which lacks the cleavage site and is
fused with streptavidin to form a chimeric protein (SA-FasL)71. This novel
molecule has two important features; i) forms oligomers owing to the structural
features of streptavidin and ii) binds to biotinylated biologic and non-biologic
surfaces for transient display (Figure 3). Several studies have shown the
feasibility of attaching SA-FasL to biotinylated islets, cardiac tissue, or
splenocytes72-74. Importantly, immunomodulation with SA-FasL-engineered cells
and tissues resulted in apoptosis of alloreactive T cells and induction of tolerance
without detectable chemotactic function for neutrophils 74.
In the context of islet transplantation as a cure for type 1 diabetes, we
showed that rapamycin as an mTOR inhibitor works in synergy with SA-FasL to
induce robust tolerance as all SA-FasL-engineered islet grafts survived

in

chemically diabetic allogeneic recipients for 500 days (n=45)74. This compelling
observation lead us to investigate the underlying mechanism(s) of the long term
survival of islet grafts. Since rapamycin administration is stopped 14 days after
transplant in this protocol, and SA-FasL is almost completely absent from the
surface of cultured islets 11 days after engineering, the long term survival must
rely on a third regulatory mechanism.
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Islet transplant sites
Infusion of islets through portal vein into the liver is the only site being
practiced in the clinic. Intraportal transplants are effective in creating an
environment in which islets can sense blood glucose and secrete insulin with
appropriate response levels. Intraportal injection of islets also obviates the need
for surgery, as islets are directly injected into the portal vein. In addition,
intraportal transplant protocols may be the most well studied in humans.
However, intraportal transplants may not yield the best environment for islets,
mainly due to the instant blood-mediated inflammatory reaction, which causes
the death of many islets soon after transplantation 17. Another downside is the
higher concentration of toxic immunosuppressive drugs in the liver.
Therefore, other locations have been explored in clinical transplantations
including intramuscular75, intraperitoneal76, and intrabone77 injections of islets.
As of yet these are still experimental procedures, but they are an important step
towards discovering the optimal transplantation site which minimizes instant
blood mediated inflammatory reaction and toxicity of immunosuppressive drugs.
In the context of the recent developments using biomaterials as delivery vehicles
and for encapsulation of islets or immunomodulation, liver is not a suitable
transplant site. As such, there is a great need for the development of transplant
sites as alternatives to intraportal transplantation that will be clinically applicable
and lack the complications of transplantation into the liver.
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Hydrogel cotransplantation with islets
Hydrogels are cross-linked polymer networks that are highly hydrated.
There are various types of hydrogels with different chemical content or
polymerization features suitable to the targeted applications. Hydrogels allow
incorporation of various bioactive functionalities at specific concentrations in
order to affect the environment. For example, hydrogels incorporated with
vascular endothelial growth factor (VEGF) slowly released the protein over
several days and stimulated cells in culture78.
Among various hydrogels, polyethylene glycol (PEG) has great potential
for use in transplantation due to its safety for in vivo use and low inflammationcausing profiles79. One PEG hydrogel in particular, maleimide-terminated 4-arm
poly(ethylene) glycol (PEG-4MAL), was generated to take advantage of these
attributes in an islet transplantation setting80. As the name suggests, PEG-4MAL
is formed from a 4-arm macromer of PEG-MAL. This is then incubated with an
RGD peptide with a c-terminal cysteine, allowing for cell adhesion. PEG-4MAL
was then conjugated with VEGF and cross-linked into a hydrogel

81

. VEGF was

tested for its ability to induce angiogenisis, which is necessary for islets to get the
maximum level of engraftment and function. Encapsulation of islets in VEGF
conjugated PEG-4MAL hydrogels and delivery into small bowel mesentery in rats
resulted in engraftment, vascularization, and insulin production over the course of
four weeks81. PEG-VEGF has also been shown to be effective at modifying
vascularization and reducing inflammatory leukocyte recruitment at the graft
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when transplanted with a single donor set of islets in the epididymal fat pad in
mice and improved survival of the graft82.
Hydrogels provide a flexible and desired platform to deliver SA-FasL to the
target tissues for immunomodulation. The advantages of this approach are twofold; i) safety due to localized immunomodulation and ii) efficacy since SA-FasL
is presented at the target tissue for a robust response. To explore this potential,
our lab in collaboration with Andres Garcia lab at Georgia Institute of Technology
investigated the efficacy of PEG gels engineered with SA-FasL in inducing
tolerance to islet allografts. Garcia lab generated PEG-4MAL macromers with
biotin-PEG-thiol to create microgels which are covalently tethered to biotin.
These PEG-4MAL biotinylated microgels were shown to bind SA-FasL in a dosedependent manner, release the molecule over the course of weeks in vivo,
induce apoptosis in Fas expressing cells in vitro and induce tolerance to
unmanipulated allogeneic islets when co-transplanted with SA-FasL-engineered
PEGs under the kidney capsule.

Utilizing scaffolds for alternative transplant sites
As PEG hydrogels cannot be infused into the liver and are not
biodegradable, we also collaborated with Lonnie Shea lab at the University of
Michigan to use biodegradable and compatible microporous poly (lacto-coglycolide) (PLG) scaffolds developed by this group. The Shea lab previously
demonstrated the validity of using PLG scaffolds to transplant islets in abdominal
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adipose tissue83. Islets are loaded on this nonencapsulated platform that allows
islets to better integrate into the host microenvironment 84.

These scaffolds

loaded with syngeneic islet transplants were penetrated by host cells, and islets
were revascularized when transplanted in the epidymal fat pad84. Importantly,
these scaffolds are able to adsorb fundamental extracellular matrix components
before transplant, such as collagen and fibronectin, which then aid in a quick
restoration of euglycemia in mice85.
When used in combination with SA-FasL engineering of islets, PLG
scaffolds may synergistically improve islet engraftment and survival in animal
models of diabetes. This may work through causing apoptosis of effector T cells,
inducing immune privilege at the site of engraftment through mechanisms
promoting

Treg

inflammatory

generation,

reaction

through

and

avoiding

extrahepatic

the

instant

blood-mediated

transplantation.

We

have

demonstrated the efficacy of PLG scaffolds to induce tolerance to allogeneic
islets using two different platforms; i) PLG scaffolds were modified with biotin and
engineered with SA-FasL and loaded with unmodified islets, or ii) unmodified
scaffolds loaded with SA-FasL-engineered allogeneic islets. PLG scaffold-based
islet transplantation and immunomodulation, therefore, provide a clinically
practical approach as it obviates the need for islet engineering and intraportal
transplantation.
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CHAPTER 2: SA-FASL-ENGINEERED ISLETS INDUCE A BIPHASIC
SPATIOTEMPORAL ALLOTOLERANCE REQUIRING A PHAGOCYTE/TGFΒ/TREG AXIS

Introduction
Type 1 diabetes is an autoimmune disease caused by the destruction of
insulin-producing

beta

cells

in

the

pancreas,

resulting

in

long

term

hyperglycemia. Transplantation of allogeneic pancreatic islets was shown to be
effective in reversing hyperglycemia in patients with type 1 diabetes86. However,
allogeneic islet grafts are subject to rejection initiated and perpetuated by Teff
cells87,

88

. Therefore, approaches that specifically target Teff cells for physical

and/or functional elimination have potential to protect allogeneic islet grafts as a
curative therapy for type 1 diabetes.
T effector (Teff) cells upregulate Fas receptor (CD95/Apo-1) on their
surface following activation and become sensitive to FasL (CD178)-mediated
apoptosis, defined as activation-induced cell death (AICD)89-91. AICD is critical
for the establishment of immune homeostasis and tolerance to self-antigens89.
The pivotal role of Fas/FasL pathway in regulating T cell responses is
emphasized by the emergence of autoimmunity in cases of Fas or FasL
deficiencies54,

90

. The Fas pathway, therefore, has significant potential for the

development of therapeutic approaches to treat autoimmune diseases and
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transplant rejection. However, the pursuit of tissue-targeted expression of FasL
for immunomodulation in settings of autoimmunity and transplantation has
produced conflicting observations92-95 that potentially arise from the complex
nature of FasL expression, the existence of two different isoforms, and the
pleiotropic and opposing functions performed by each isoform.

FasL is

expressed as a type II membrane-bound protein, which can be cleaved by matrix
metalloproteinases into soluble form in response to environmental cues 66. The
membrane-bound form was reported to have apoptotic activity, while the soluble
form lacks such activity and serves as a chemotactic factor for neutrophils69, 96.
These initial observations were further confirmed in transgenic mice expressing
either a soluble or membrane-bound form of FasL97. The membrane-bound form
was shown to be apoptotic and essential for controlling autoimmunity, while the
soluble form promoted autoimmunity and tumorigenesis via non-apoptotic
functions.

Therefore,

the

therapeutic

application

of

FasL

as

an

immunomodulator may require a form that primarily has apoptotic function.
We have previously reported71 the generation a novel form of FasL
chimeric with a modified form of core streptavidin (SA-FasL). This molecule
forms spontaneous oligomers in solution and has robust apoptotic activity on
Fas-expressing lymphocytes. Importantly, SA-FasL can be transiently displayed
on the surface of biotinylated cells, tissues, or organs for systemic or localized
immunomodulation72, 74, 98, 99. Systemic immunomodulation with donor SA-FasLengineered splenocytes resulted in tolerance to cardiac allografts in rodents99,
and facilitated the engraftment and survival of hematopoietic stem cells in
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allogeneic hosts100.

Localized immunomodulation using SA-FasL-engineered

islet allografts resulted in indefinite graft acceptance in a chemically diabetic
BALB/c-to-C57BL/6 mouse model74.
We herein investigated the mechanistic basis of tolerance achieved by
SA-FasL-engineered allogeneic islets and report that tolerance is initiated by a
regulatory loop consisting of apoptosis, phagocytes, and TGF-β. Importantly,
tolerance at the induction phase is donor-specific and systemic, and evolves into
graft site-restricted immune privilege requiring Treg presence at the maintenance
phase.

Materials and Methods
Mice and Recombinant Proteins
C57BL/6, B6.Cg-Foxp3tm2(EGFP)Tch/J, BALB/c, and C3H mice were obtained from
Jackson Laboratories).

C57BL/6.SJL and TCR transgenic OT-I and OT-II mice

on Rag2-/- background were purchased from Taconic Farms. BALB/c.RIP-OVA
mice were a gift from Dr. S. Webb, Scripps Research Institute, La Jolla, CA.
Animal were kept in our specific pathogen-free animal housing facility at the
University of Louisville using protocols approved by the Institutional Animal Care
and Use Committee. Recombinant SA and SA-FasL proteins were produced in
our laboratory using the Drosophila DES expression system (Invitrogen) as
previously described 71.

Pancreatic Islet Isolation, Engineering, and Transplantation
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Pancreatic islets were harvested from 8 to 12-week-old donors under anesthesia
using a standard protocol

71

. Islets were engineered with SA-FasL or SA control

proteins as described74 and ~500 islets were transplanted under kidney capsule
of streptozotocin chemically induced diabetic mice (confirmed by BG ≥ 300 mg/dl
for two consecutive days). Selected groups of mice were given i.p. injections of
rapamycin (0.2 mg/kg) starting on the day of transplantation daily for 15 days.
Animals were monitored for blood glucose levels and those with two consecutive
daily measurements of ≥ 250 mg/dl were considered diabetic and rejecting the
graft.

Skin and Heart Transplantation
Donor tail skin was harvested from euthanized mice, cut into 2 cm square, and
grafted on dorsal area of recipients under anesthesia. Animals were bandaged
and bandage was removed 7 days post-transplant. Animals were monitored daily
and skin was considered rejected at 90% necrosis.

Heterotopic heart

transplantation and graft monitoring were performed as described

99

.

In Vivo Proliferation Assays
OVA CD8+ T cells were isolated from spleen and mesenteric LNs of OT-I
transgenic C57BL/6 mice, labeled with CFSE as described 101, and 15 x 106
cells/animal were transferred by tail vein injection into C57BL/B6.SJL congenic
mice. One day later, these mice were transplanted with SA- or SA-FasLengineered pancreatic islets isolated from RIP-mOVA transgenic BALB/c mice
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expressing a membranous from of OVA in pancreatic beta cells under the control
of rat insulin promoter102. Lymphocytes were harvested from kidney-draining
LNs, mesenteric LNs, and spleens 5 days after islet transplantation and stained
with antibodies against CD8-PerCp, V-5-PE, and CD45.2-APC. Proliferation of
OT-I cells were determined by gating on V-5+CD8+CD45.2+ T cells.
Splenocytes were isolated from C57BL/6 mice with long-term syngeneic
and allogeneic graft acceptors and rejectors, labeled with CFSE, and injected by
tail vein into naive F1 (C57BL/6 x BALB/c, H-2b/d) or (C57BL/6 x C3H, H-2b/k)
mice as donor and third party antigenic controls, respectively.

After 72 h,

lymphocytes were harvested from the spleen and stained with antibodies against
H-2Kb-PE and H-2Kd-APC or H-2Kk-PE to differentiate between donor and
recipient cells. The cells were run on the FACSCalibur and the data was
analyzed using FlowJo software.

Phagocyte Depletion and Treatment with Anti-TGF- Antibody
Selected

groups

of

mice

were

injected

intravenously

with

dichloromethylenediphosphonic acid (DMDP, Clodronate) or PBS loaded
liposomes (Enca Encapsula NanoSciences) one day prior to islet transplantation.
Depletion of macrophages and immature DCs in peripheral blood were assessed
using antibodies against F4/80, CD11b, and CD11c at various times posttreatment.
For blocking TGF-β in vivo, mice were treated either with 300 µg/mouse
monoclonal antibody (1D11) to TGF-β1, 2, and 3 on days -1, +1, +3, and +5
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post-transplantation (n = 2) or 1 mg/mouse on days -1, +1, +3, +5, and +6 posttransplantation (n = 3), or 0.5 mg/mouse on days 100, 102. 104, 106 posttransplantation (n = 4). A blocking antibody (JES5-2A5) to IL-10 was used at 1
mg/mouse on days -1, +1, 3, 5, and 6 post-transplantation (n = 5).

Analysis of TGF- production by T cells undergoing apoptosis and
macrophages engulfing apoptotic bodies
CFSE labeled OT-II T splenocytes were activated with OVA for 72 hrs and live
cells were isolated by Lympholyte density separation and incubated with SAFasL or SA protein (equal molarity to SA-FasL) as control for 16-18 hrs. Cells
were washed extensively, labeled with Annexin V, 7AAD, and CD4 and analyzed
using multiparameter flow cytometry.
Peritoneal macrophages were cultured in 24-well plates at 2 x 106
cells/well and incubated for 1 hour in serum free medium at 37 oC in a 5% CO2
incubator. Non-adherent cells were washed out and adherent macrophages were
cocultured with apoptotic OT-II cells at 1:3 ratio in serum free media for 18 hrs.
To remove non-engulfed apoptotic cells, wells were washed extensively with
PBS and fixed with 4% of paraformaldehyde for 20 minutes at room temperature.
After FcII/III receptor blockade and permeabilization, cells were stained with a
mouse anti-TGF-β antibody (R&D systems) for 45 minutes at 37 oC and the
binding was visualized using Alexa 546-labeled anti-mouse IgG antibody
(Invitrogen).

Macrophages were identified by Alexa 647-labeled anti-F4/80
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antibody (Caltag Laboratory). Cells were analyzed using confocal microscopy for
the uptake of apoptotic bodies (green) and production of TGF- (blue).

Immunohistochemical analyses
The kidney harboring islet graft was snap-frozen in Tissue-Tek O.C.T. compound
(Sakura FineTek), cut into 5-8 m thick sections using a Bright OTF5000
cryomicrotome (Rose Scientific Ltd.).

For TGF-β staining, primary and

secondary Ab complexes were first prepared by mixing 1:1000 dilution of antiTGF-β Ab (clone 1D11) or mouse IgG1 isotype control in PBS with equal volume
of 1:300 dilution of Alexa 546-labeled goat anti-mouse Ab followed by rotating for
18 hrs at 4°C.

Antibody complexes were then blocked with heat-inactivated

mouse serum (0.1% v/v) by incubating on rotator at 4°C for 2 hrs.

Tissue

sections were then fixed in 1:1 ice cold acetone-methanol for 10 minutes at room
temperature (RT), washed, and incubated in 2% paraformaldehyde for 10
minutes at RT. Tissue sections were then incubated in a blocking solution (1%
BSA, 5% goat serum and 1:400 FcII/III receptor block) for 30 minutes at RT
followed by staining first with Alexa647-conjugated rat anti-mouse F4/80 Ab
(1:100 dilution, Caltag laboratories) in 1% BSA for 1 hour at 37°C. After washing
twice with PBS, tissue sections were then stained with anti-TGF-β or isotype Ab
complexes by incubation for 4 hrs at room temperature. Hoechst (Molecular
Probes) was used to stain DNA in the tissue. Fluorescent images were obtained
using a Leica TCS SP5 confocal microscope under 20X magnification.
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Statistical Analyses
The Welch’s t-test was used to determine difference between two groups except
in the supplemental data which used an unpaired two-tailed t-test. Graft survival
statistical difference was assessed using the log-rank test. Data are expressed
as mean ± SD. P values of < 0.05 were considered significant.

Statistical

analysis and graph creation was performed using GraphPad Prism software.

Results
Reduced frequency of proliferating alloreactive T cells in lymph nodes
draining FasL-engineered islet grafts
We have previously shown that pancreatic islets engineered to display
SA-FasL protein on their surface overcame rejection in chemically diabetic
allogeneic hosts74. Graft survival was associated with apoptotic depletion of Teff
cells within islet grafts74. To assess if the depletion of alloreactive T cells is
systemic, CFSE-labeled OT-I CD8+ T cells (CD45.2) recognizing a dominant
epitope of ovalbumin (OVA) were adoptively transferred into congenic
C57BL/6.SJL mice (CD45.1) one day before sub-renal capsule transplantation of
islets from OVA transgenic BALB/c (RIP-OVA) donors. We observed a marked
increase in the percentage of proliferating OT-I cells (~ 54%) in the kidney
draining lymph nodes of recipients transplanted with control streptavidin (SA)engineered islets (Figure 4A). OT-I cells also showed significant, but less robust
proliferation in the lymphoid tissues distant from the graft, such as mesenteric
lymph nodes (~15%) and the spleen (~24%). In marked contrast, significantly
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lower percentages of proliferating OT-I cells were detected in the same three
tissues of recipients transplanted with SA-FasL-engineered BALB/c RIP-OVA
islet grafts, with the decrease being more pronounced (> 5-fold) in graft draining
LNs. These observations are consistent with the reported critical role of graftdraining lymph nodes in regulating alloreactive immunity87. Furthermore, these
results show that the impact of SA-FasL on alloreactive T cells is not systemic,
but rather primarily localized to the graft74 and graft draining lymph nodes as
shown here.

Systemic donor-reactive responses persist despite long-term islet graft
acceptance
The reduced proliferative response of donor-reactive T cells in SA-FasLengineered islet graft recipients (Figure 4A) in the early phase of tolerance
induction may evolve into two different outcomes at the maintenance phase;
establishment of generalized tolerance and consequent unresponsiveness to
donor antigens or localized immune privilege in spite of persistent donor-reactive
responses. We first confirmed our previous observations74 by demonstrating that
transplantation of SA-FasL-engineered BALB/c islets into chemically diabetic
C57BL/6 mice under transient cover of rapamycin (15 daily doses) results in
long-term graft survival (Figure 4B). This tolerogenic effect was dictated by SAFasL as islet grafts engineered with streptavidin as control protein transplanted
using the same rapamycin regimen were acutely rejected (n=3; MST 24±2.3).
We next tested if tolerant graft recipients generate a systemic donor-reactive
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response. An in vivo proliferation assay was used to assess the status of donorspecific immune responses in acceptors of SA-FasL-engineered islet grafts. T
cells harvested from the spleen of long-term (> 100 days) SA-FasL-islet graft
recipients generated a strong in vivo proliferative response against both donor
(BALB/c) and third party (C3H) antigens (Figure 4C).

The donor-reactive

response was of similar magnitude to those generated by T cells from long-term
syngeneic or rejecting control SA-engineered allograft recipients.

An intact

systemic T cell response to the donor antigens in long-term SA-FasL-engineered
islet allograft survivors is consistent with the demonstrated role of FasL in
physiological immune privilege 103, 104.

Phagocytes are required for tolerance induction
Apoptotic lymphocytes were shown to have immunomodulatory features
involving phagocytes and TGF-β105, 106. We, therefore, next investigated the role
of phagocytes in the induction of tolerance in our model. Depletion of
macrophages and immature DCs using clodronate loaded liposomes (Figure 5)
one day before transplantation resulted in acute rejection of SA-FasL-engineered
islet grafts in all recipients (Figure 6A; n = 7, MST = 24 ± 9.6 days). In marked
contrast, all the mice treated with empty liposome (no clodronate) showed graft
survival over an observation period of 100 days (n = 5, MST >100 days),
supporting a critical role of these cells in the induction of tolerance.
Immunohistochemical analysis revealed more F4/80+ macrophages
localized in the periphery of SA-FasL engineered islets early post-transplantation
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(day 5) as compared with SA-engineered control islet grafts (Figure 6C). SAFasL-engineered islets scored positive for TGF-, while this cytokine was
undetectable in SA-engineered control islets (Figure 6C). Consistent with these
in vivo observations, we demonstrated using in vitro cultures that both T cells
undergoing SA-FasL-mediated apoptosis (data not shown) and macrophages
engulfing apoptotic bodies from T cells produce TGF- (Figure 6D). However, it
remains to be investigated if TGF- secreted by macrophages contributes to
tolerance seen in this model. Taken together, these results demonstrate the
critical role of phagocytes in the induction phase of tolerance attained by SAFasL-engineered allogeneic islet grafts.

TGF- is required for the induction, but not the maintenance of tolerance
IL-10 and TGF-β are immunoregulatory cytokines, and in particular TGF-β
has been implicated in tolerance involving T cell apoptosis in various models 105107

.

We, therefore, tested the role of these cytokines in the induction and

maintenance of tolerance. Recipients of SA-FasL-engineered allogeneic islets
were treated intravenously with a blocking antibody to TGF- and IL-10.
Neutralization of TGF- at the induction phase of tolerance resulted in acute
rejection of all SA-FasL engineered islet grafts (Figure 6B; n = 5, MST = 22 ± 4.9
days), whereas antibody treatment at the maintenance phase of tolerance (100
days post-transplantation) had no impact on graft survival (n = 4 MST > 60 days
post injection). In marked contrast, treatment with a blocking antibody against IL10 as another regulatory cytokine at the induction phase did not affect long-term
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acceptance of SA-FasL-engineered islet grafts (Figure 6B; n = 5, MST > 100
days). These results demonstrate the critical role of TGF- in the induction, but
not maintenance, phase of tolerance.

Tolerance is systemic at the induction phase and shows both donor and
tissue specificity
We have previously shown that long-term tolerance achieved by SA-FasLengineered islet grafts is localized to the graft and requires Treg cells for
maintenance74. Treg cells were shown to traffic to allogeneic pancreatic islets
immediately post-transplantation in response to inflammatory cues, where they
manifest their immunoregulatory function within the graft microenvironment87, 108.
Therefore, we assessed if the SA-FasL-mediated long-term, localized tolerance
is systemic at the induction phase using a simultaneous two-islet graft model.
C57BL/6 mice were transplanted with BALB/c SA-FasL-engineered islets under
the right kidney capsule and unmanipulated islets from BALB/c or C3H third party
donors under the left kidney capsule. These animals were also subjected to a
short course of rapamycin (0.2 mg/kg) administered daily for 15 days starting the
day of transplantation.

Surgical removal of the kidney harboring SA-FasL-

engineered islet graft 60 days post-transplantation did not result in hyperglycemia
in

recipients

transplanted

with

donor-matched,

unmodified

islet

grafts,

demonstrating the survival and function of unmodified donor grafts (Figure 7A; n
= 4, MST > 100 days). Importantly, tolerance in this group was maintained by
Treg cells as their depletion using an antibody to CD25 resulted in rejection of

37

38

39

3/4 grafts within 22 days (Figure 7B). The mouse that did not reject the graft had
minimal depletion of Treg cells (Figure 8). This is concordant with previous
results demonstrating the rejection of SA-FasL-engineered grafts after Treg
depletion74. In marked contrast, surgical removal of the SA-FasL-engineered
BALB/c islet graft resulted in prompt hyperglycemia in recipients transplanted
with the unmodified C3H third party islet graft, thus demonstrating that tolerance
requires antigen-specificity (Figure 7C, n = 5).
We next used the simultaneous two-graft model to determine the tissuespecific nature of tolerance at the induction phase.

C57BL/6 mice were

transplanted with BALB/c SA-FasL-engineered islets and donor-matched or C3H
third party skin grafts under the transient cover of rapamycin. Both donor and
third party skin grafts were acutely rejected (Figure 7D). Rejection of BALB/c
skin also triggered rejection of SA-FasL-engineered BALB/c islets, causing
development of hyperglycemia within 30 days (Figure 7E; n = 4, MST 26 ± 2.6
days). In marked contrast, the rejection of C3H skin did not interfere with longterm acceptance of BALB/c SA-FasL-engineered islets as all mice remained
euglycemic for an observation period of 60 days (Figure 7E; n = 4, MST > 60
days).

Because skin grafts elicit vigorous allogeneic immune responses, we

next assessed the survival of heart allografts. Similar to skin grafts, BALB/c
heart grafts transplanted simultaneously with SA-FasL-engineered islets were
rejected, albeit in a delayed tempo as compared with control heart allografts
alone (Figure 7F; MST = 25 ± 1.7 vs 12 ± 0.9 days for controls, P = 0.0169).
Heart graft rejection also caused hyperglycemia, an indication of SA-FasL-
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engineered islet graft rejection (Figure 7F; n = 3, MST = 25 ± 2.0 days). Taken
together, these results demonstrate that localized immunomodulation with SAFasL-engineered islets evolves into systemic tolerance at the induction phase
that is both donor- and tissue-specific.

SA-FasL-engineered islets establish a donor-specific immune privilege site
that requires the graft for maintenance
Although FasL has been implicated in physiological immune privilege103,
104

, the direct evidence for such a role in induced immune privilege remains to be

provided. To assess if the SA-FasL-engineered islet graft induces an immune
privileged site, long-term (> 60 days) recipients were treated with streptozotocin
to destroy the graft. A group of mice were transplanted with a second set of
unmodified donor-matched or C3H third party islet grafts into the same site of the
primary graft 4 days after the confirmation of hyperglycemia. The second set of
BALB/c islet grafts restored euglycemia in all recipients for an observation period
exceeding 70 days (Figure 9B; n = 5).

In marked contrast, third party islet

allografts established euglycemia only for 20 days, demonstrating acute graft
rejection (Figure 9B; n = 5, MST = 19 ± 2.7 days).
To test whether alloantigens expressed by the graft are the driving force
for the maintenance of induced immune privilege, a second set of long-term (> 60
days) graft recipients were injected with streptozotocin and maintained for 20
days with exogenous insulin, a period considered to be sufficient for clearance of
the injured graft. Transplantation of unmodified donor-matched second set of
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islet grafts under the same kidney capsule that harbored the primary graft
resulted in temporary euglycemia and rejection of all grafts in an acute fashion
(Figure 9C; n = 5, MST = 16 ± 2.1 days). These data demonstrate a requirement
for the continued presence of islet alloantigens for the maintenance of induced
immune privilege site.

Immune privilege cannot be extended to a second set of unmanipulated
islet grafts transplanted to a distant site under the cover of rapamycin
The two-islet graft model showed that peripheral tolerance is systemic at
the induction phase and requires a short course of rapamycin. This agent works
in synergy with Fas-mediated apoptosis to eliminate Teff cells63, 109 and also has
a positive effect on the generation, maintenance, and function of Treg cells27, 43,
110

. Inasmuch as the localized tolerance in our model was maintained by Treg

cells (Figure 7B), we tested if rapamycin can expand and/or mobilize Treg cells
from long-term surviving primary grafts into the second set of donor graft
transplanted at a distant site. Long-term (80 days) acceptors of SA-FasLengineered BALB/c islets were transplanted with a second set of unmodified,
donor-matched islet grafts under the contralateral kidney capsule under the same
rapamycin regimen used for the induction of tolerance. Surgical removal of the
primary graft 40 days after transplantation of the secondary graft resulted in
prompt hyperglycemia within 3 days (Figure 9D, n = 3). These data confirm our
previously published studies demonstrating that tolerance at maintenance phase

45

is localized

74

, and further show that rapamycin at this phase cannot

mobilize/extend tolerance to a secondary graft placed in a distant site.
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CHAPTER 3: LOCAL IMMUNOMODULATION WITH SA-FASL-ENGINEERED
BIOMATERIALS ACHIEVES ALLOGENEIC ISLET GRAFT ACCEPTANCE

IntroductionCurrent clinical treatments for type 1 diabetes rely on direct injection into
the portal vein, exposing the graft to the blood, which leads to the death of 5080% of transplanted islets through instant blood-mediated inflammatory reactions
(IBMIR)111,

112

. Other sites for transplant have been explored, including kidney,

spleen, and omentum113, or the murine version of omentum, epididymal fat pad
(EFP)114.

These extrahepatic sites for transplant have varying degrees of

vascularization and inflammatory responses to islet transplants, which leads to
different levels of engraftment and islet survival.
As such, type 1 diabetes patients might greatly benefit from alternative site
transplantation where IBMIR and inflammatory responses are reduced, yet islets
are sufficiently vascularized. This may be achievable through transplantation in
conjunction with biomaterials such as maleimide-terminated 4-arm poly(ethylene)
glycol (PEG-4MAL) and poly (lacto-co-glycolide) (PLG). PEG-4MAL with VEGF
tethered to the hydrogel network and slowly released through proteolytic
degradation was shown to increase vascularization of islets transplanted at the
epididymal fat pad in mice82.
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These hydrogels may also be used in conjunction with SA-FasL to control
the immune response to engrafted islets. Integrating biotin into the PEG-4MAL
gels and then engineering with SA-FasL could allow for the slow release of SAFasL as the gels degrade, allowing for continuous immunosuppression in the
area of the graft.
PLG scaffolds also show promise for enabling clinical islet transplants at
extrahepatic sites. Islets can be seeded into the pores of the scaffold, which then
allows for integration with the host tissue. PLG scaffolds transplanted with islet
grafts in the EFP of mice allow for islet vascularization and nutrient diffusion due
to their high porosity115, 116. Further experimentation showed that decorating PLG
scaffolds with collagen IV, which is important in extracellular matrix structure,
resulted in an increase in function of the transplanted islets115, 117.
In this chapter, we study the ability of PLG scaffolds and PEG-4MAL
hydrogels in combination with SA-FasL and a short course of rapamycin to
induce long-term tolerance to allogeneic islets in a chemically induced mouse
model of BALB/c-to-C57BL/6. We also engineer biomaterials with SA-FasL
alongside islet engineering with SA-FasL to induce tolerance to islets without
additional immunosuppression in the same allogeneic model.

Materials and Methods
Islet transplantation. BALB/c pancreatic islets were isolated using Liberase TL
as a digestive enzyme (Roche Life Science) and purified by a Ficoll density
gradient as previously published118. To biotinylate islets, overnight cultured islets
were incubated in 5 μM EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific) for 30
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min at room temperature, washed extensively with PBS to remove unbound
biotin solution. Biotinylated islets and microgels were engineered with SA-FasL
(~150 ng/500 islets and 1-10 µg/1000 microgels). In select groups, unengineered
islets or microgels or both were used in place of SA-FasL engineered islets or
microgels. Approximately 500 islets were co-transplanted with 1000 microgels
into

streptozotocin

diabetic

(>

250

mg/dL)

C57BL/6

or

B6.129(Cg)-

Foxp3tm3(DTR/GFP)Ayr/J (C57BL/6.FoxP3EGFP/DTR) recipients, where indicated. For
Treg depletion, islet graft recipients were injected i.p. with diphtheria toxin (50
µg/kg body weight) and depletion was confirmed 3 days later in peripheral blood
lymphocytes using flow cytometry. Selected groups were also treated i.p. with
rapamycin at 0.2 mg/kg daily for 15 doses starting the day of transplantation. In
select groups of mice, islets were loaded onto PLG scaffolds (2/mouse). Diabetic
mice were given anesthesia and a small incision was made on the abdomen to
allow scaffolds to be placed on epididymal fat pads. Adipose tissue was wrapped
around scaffolds before being returned to the abdomen. Mice were then sutured.
Select biotin-PLG scaffolds were engineered by placing scaffolds to a round
bottom tube and adding SA-FasL (0.5 or 2.5 µg /scaffold) diluted in PBS and
incubating at 20oC for 30 minutes while rotating and shaking the tube every 10
minutes. Scaffolds were washed twice before being loaded with islets.
Unmodified BALB/c islets co-transplanted with unmodified PEG gels or loaded
onto unmodified PLG scaffolds were used as controls. Animals were monitored
for blood glucose and ≥ 250 mg/dL blood glucose levels for two consecutive daily
measurements were considered rejected. Data was graphed using GraphPad
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Prism and log-rank test was used to determine significance between groups, p <
0.05 was considered significant.

Intraperitoneal Glucose Tolerance Test
Mice were put in clean cages without food and allowed to fast for 6 hours.
After fasting, mice were injected with 25% glucose solution (2 gm/kg body
weight). Mice were monitored for blood glucose levels before injection and at 10,
20, 30, 60, 90, and 120 minutes post glucose injection.

Immune monitoring. Spleen, kidney, and kidney draining lymph nodes were
harvested from rejecting and long-term mice (> 200 days). Single cells were
prepared from the spleen and lymph nodes by gentle mechanical dispersion and
from islet harboring kidney by collagenase digestion. Cells were stained using
antibodies to cell surface markers (Alexa 700-CD4 Ab, APC-Cy7-CD8 Ab, PECy7-CD25 Ab from Pharmingen, BD, and eFlour 450-CD44 Ab and PerCPCy5.5-CD62L Ab from eBioscience). Intracellular FoxP3 staining was carried out
on fixed/permeablized cells using FoxP3 Transcription Factor Staining Buffer set
(eBioscience). For mixed lymphocyte reaction, splenocytes were panned and
labelled with CFSE. Stimulator cells were prepared from either naïve BALB/c
(donor) or C3H (3rd party) mice, irradiated with 200 cGy, and cocultured with
equal numbers of responder cells in 96-well plates (0.1x106 cells/well). Cells
were cultured in 200 µl DMEM supplemented with HEPES buffer, sodium
pyruvate, penicillin/streptomycin, L-Glutamine (ThermoFisher Scientific), FBS, L-
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Arginine HCL, folic acid, L-Asparagine, 2-Mercaptoethanol (Sigma), and
responder serum. Cells were harvested after four days of culture at 37°C and
stained with Alexa 700-CD4 Ab, APC-Cy7-CD8 Ab, and 7AAD to separate dead
cells (BD Pharmingen). Data was collected using BD LSR II and analyzed using
Diva software. Data was graphed using GraphPad Prism and Welch’s t test was
used to determine significance between groups, p < 0.05 was considered
significant.

Proliferation assay. Splenocytes harvested from selected group of transplant
recipients were labeled with CFSE and used as responders to irradiated (2000
cGy) splenocytes from donor or third party C3H mice in a standard in vitro
proliferation assay74. After 4 days in culture, cells were stained with 7AAD and
fluorescence-conjugated Abs against CD4 and CD8, and analyzed for CFSE
dilution by gating on live cells using BD LSR II. Data was analyzed using Diva
software. Data was graphed using GraphPad Prism and Welch’s t test was used
to determine significance between groups, p < 0.05 was considered significant.

Confocal Microscopy. After the observation period of 200 days, long-term islet
bearing kidneys were snap frozen in OCT compound (Sakura Tissue-Tek) by
submerging in methyl butane (Sigma) on dry ice. Tissues were cut in 10 µm-thick
slices using a Bright OTF5000 cryomicrotome (Rose Scientific) and put on
frosted slides for staining. Slides were fixed in 4% paraformaldehyde, incubated
in 0.5% Triton X-100, and blocked in 0.1% bovine serum albumin, 5% goat
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serum, and rat anti-mouse CD16/CD32 (BD Pharmingen). Staining was
performed using rabbit anti-glucagon mAb (Cell Signaling) and guinea pig antiinsulin polyclonal antibody (Dako) as primary antibodies, followed by washing
and staining with AlexaFluor-647-conjuaged goat anti-rabbit antibody (Life
Technologies)

and

AlexaFluor-555-conjugated

anti-guinea

pig

antibody

(Invitrogen). Hoechst 33342 (Molecular Probes) was used to stain DNA.
Fluorescent images were obtained using a Leica TCS SP5 confocal microscopy
under 10X magnification.

Statistical analysis
Flow data was tested for significance using a two tailed Welch’s t-test. Graft
survival was tested for significance using the log-rank test. P values of <0.05
were considered significant. Survival curves, IPGTT, and flow graphs were
created and analyzed using GraphPad Prism software.

Results
SA-FasL-engineered microgels induce apoptosis
Herein, we engineered a novel biomaterial for the sustained presentation
of SA-FasL within the islet graft microenvironment. This approach eliminates the
need

for

islet

modification

and

establishes

a

translatable,

effective

immunomodulatory strategy that does not require chronic immunosuppression.
Hydrogel microparticles (microgels) were synthesized from maleimide-terminated
4-arm poly(ethylene) glycol (PEG-4MAL) macromers using microfluidics
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polymerization119. The PEG-4MAL platform enables stoichiometric, covalent
incorporation of thiol-containing molecules, and provides improved crosslinking
efficiency for formation of structurally defined hydrogels80. PEG-4MAL exhibits
minimal toxicity in vivo, and it is rapidly excreted in the urine79, important
considerations for clinical applications. Biotinylated microgels were produced by
reacting biotin-PEG-thiol with PEG-4MAL macromer, and generating 150 μm
diameter microgels crosslinked with dithiothreitol (DTT) via microfluidics
polymerization (Figure 10A). The resulting microgels displayed covalentlytethered biotin capable of capturing SA with high affinity (Figure 10B). These
results show that SA-FasL can be tethered to biotinylated microgels.

Long-term

islet

allograft

survival

induced

by

SA-FasL-engineered

microgels
The immunomodulatory efficacy of microgels presenting SA-FasL was
tested in an allogeneic islet transplantation setting. Unmodified allogeneic
(BALB/c) islets were mixed with microgels, and the resulting mixture was
transplanted under the kidney capsule of streptozotocin-diabetic C57BL/6 mice.
Mice receiving unmodified islets and control biotinylated microgels acutely
rejected all grafts [median survival time (MST) = 14.6 ± 1.7 days; Figure 11A].
Islets co-transplanted with SA-FasL-engineered microgels had significantly
prolonged survival (MST = 37.6 ± 9.0 days). The presentation of SA-FasL on
both microgels and biotinylated islets further delayed rejection with four grafts
rejecting within 59 days and one graft surviving for the 200-day observation
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period. The improved performance of this group suggests a dose-dependent
immunomodulatory effect for SA-FasL. This was confirmed in mice receiving
microgels engineered with 10 times more SA-FasL protein which further
improved graft survival as 2/5 unmodified islet grafts did not show signs of
rejection by the 200-day experimental end-point (Figure 11A, B). Notably, all
grafts (n=5) functioned and survived for the entire 200-day observation window in
mice co-transplanted with unmodified islets and SA-FasL-presenting microgels
when subjects were treated with a short course of rapamycin (0.2 mg/kg daily
initiated on day 0 post-transplantation for 15 doses; Figure 11A, 12).
Intraperitoneal glucose tolerance tests demonstrated equivalent function of these
long-term grafts compared with naïve mice (Figure 11C). In marked contrast, the
same protocol with rapamycin injections but without SA-FasL-engineered
microgels resulted in acute rejection (MST = 20.6 ± 3.9 days) (Figure 11A).
Taken together, these results show that simple co-transplantation of allogeneic
islets and SA-FasL-engineered microgels restores long-term glycemic control
without the use of chronic immunosuppression or islet modification.

Tregs required for long-term survival of islets in mice treated with SA-FasLengineered microgels
Because of the localized nature of immunomodulation, we assessed the
systemic response of graft recipients to donor antigens in an in vitro proliferation
assay. Both CD4+ and CD8+ T cells from long-term (> 200 days) islet graft
recipients treated with SA-FasL-engineered microgels showed proliferative
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responses to donor as well as third party antigens (Figure 13A). The observed
responses were at similar magnitudes to those obtained using T cells from
rejecting mice receiving unmodified microgels plus rapamycin. This result
indicates that mice receiving SA-FasL-engineered microgels maintain systemic
immune competence, and that the protection afforded by SA-FasL-engineered
microgels remains localized to the graft, as reported previously in two transplant
settings using FasL as an immunomodulatory molecule74, 120.
To further elucidate the mechanism of graft acceptance, immune cell
populations harvested from the spleen, graft draining lymph nodes (LNs), and the
graft were analyzed using flow cytometry in a time-course study, with particular
focus on Teff and T-regulatory (Treg) cells as targets of FasL-mediated
immunomodulation. We observed a trend towards an increased ratio of Treg to
CD4+ and CD8+ Teff cells in the graft (p < 0.05 for Treg:CD8+ Teff) and Treg to
CD4+ and Teff cells in graft draining LNs (p < 0.05 for Treg:CD4+ Teff population)
in groups receiving SA-FasL-engineered microgels and rapamycin compared to
control groups receiving unmodified microgels alone or in combination with
rapamycin (Figure 13B). Treg cells, similar to Teff cells, follow the inflammatory
cues and infiltrate into rejecting grafts without a functional consequence121, 122. As
such, we conducted a depletion study to directly assess the role of Treg cells in
the observed graft acceptance in our model.

For these studies, BALB/c

allogeneic islets were transplanted into transgenic C57BL/6 mice expressing
human diphtheria toxin (DT) receptor under the control of Foxp3. Chemically
diabetic transgenic mice transplanted with allogeneic islets and SA-FasL-
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engineered microgels under the transient cover of rapamycin established graft
acceptance, as seen previously in C57BL/6 recipients, with all mice maintaining
graft function at day 50 post-transplantation. Depletion of Treg cells by
administration of DT on day 50 resulted in rejection of all grafts by day 82 (Figure
13C; MST = 72.2 ± 10.2 days), demonstrating the dominant role of this cell type
in graft acceptance.

Transplantation of SA-FasL modified islets on microporous scaffolds
We investigated the transplantation of SA-FasL modified islets on
microporous scaffolds implanted into the epididymal fat pad (Figure 14A). Initial
studies employed syngeneic islets transplanted into streptozotocin-induced
diabetic mice to determine the impact of the scaffolds and short term rapamycin
on the engraftment and function of the islets. Transplantation of the syngeneic
islets led to the establishment of euglycemia within 10 days for all animals, and
the animals maintained euglycemia for the duration of the study (100 days)
(Figure 14B). Subsequently, allogeneic islets modified with SA-FasL were
transplanted on microporous scaffolds. Unmodified islets transplanted on
scaffolds with transient rapamycin had rejection of the grafts, as indicated by
increased blood glucose levels, by day 30 (Figure 14B). Mice transplanted with
allogeneic islets modified with SA-FasL and receiving transient rapamycin had
normalized blood glucose levels that were sustained for 200 days (Figure 14B),
similar to the results with syngeneic islets. Rapamycin has been previously
reported to synergize with FasL presentation to prolong graft survival74, as either
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factor alone results in only short-term graft function. An intraperitoneal glucose
tolerance test (IPGTT) study demonstrated that the normalization of blood
glucose levels by the transplanted islets was similar to that observed with naïve
mice (i.e., non-diabetic) (Figure 14C), which is consistent with previous reports of
islets transplanted on scaffolds116, 123.
T cell proliferative responses were analyzed from the spleens. The collected
cells were labeled with CFSE and used against BALB/c donor and third party
C3H stimulators in a standard ex vivo mixed lymphocyte reaction. After 4 days of
culture, the responses from CD8 T cells indicated similar proliferative responses
for the SA-FasL islets, the unmodified islets, and an age-matched C57BL/6
control, with responses similar to both the donor and third party stimulators
(Figure 14D). Interestingly, CD4 T cell responses were greater for the SA-FasL
modified islets relative to either the unmodified islets or age-matched control.
This response was similar for both the donor and third party stimulators. These
results demonstrate that CD4 and CD8 responsiveness is maintained outside the
graft. Collectively, these studies demonstrate that the microporous scaffolds for
transplantation of FasL modified islets to an extrahepatic, extra-renal site
provides for engraftment of the islets and protection from the immune response
similar to previous reports performed with transplantation into the kidney capsule
or liver74, 124.
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FasL scaffolds support allogeneic graft function without sustained
immunosuppression
We subsequently investigated whether SA-FasL modified scaffolds could
prevent allogeneic islet rejection similar to the SA-FasL modified islets, while also
supporting engraftment and long-term function to maintain normoglycemia.
Scaffolds decorated with SA-FasL were loaded with islets from BALB/c donors
and transplanted into the epididymal fat pad of diabetic C57BL/6 mice. Naïve
islets mounted on SA-FasL-engineered PLG scaffolds along with transient
rapamycin demonstrated graft survival for more than 200 days in more than 80%
of the animals (Figure 15A), with one animal rejecting at day 30. Rapamycin
without FasL had a mean graft survival time of 23.6±2.2 days (Figure 15A, B).
Interestingly, when both islets and scaffolds were conjugated with FasL but did
not receive the short course rapamycin treatment, one third of the mice
established long-term tolerance while the rest rejected by day 50. For the
transplantation of islets on SA-FasL modified scaffolds, normoglycemia was
established within days of transplantation (Figure 15B). The blood glucose
dynamics were similar between the SA-FasL-modified scaffolds and the
unmodified scaffolds (with rapamycin) through day 20, at which point, the blood
glucose levels began to rise for the unmodified scaffolds likely due to rejection of
the islets. An IPGTT performed at day 200 demonstrated restoration of
normoglycemia at a rate that was similar to naïve animals (Figure 15C).

66

67

68

CHAPTER 4: DISCUSSION

The studies done in chapter 2 show that SA-FasL-engineered pancreatic
islets induce a biphasic, spatiotemporal tolerance to allografts. This tolerance
begins as systemic during the early induction phase, and becomes localized
during the maintenance phase. Despite extensive searching of the literature, we
have not found this biphasic, spatiotemporal tolerance induced in other models.
We also showed the noted ability of FasL to induce immune privilege at the site
of the graft. This immune privilege relied on phagocytes and the tolerogenic
cytokine TGF-β and required the graft and Tregs to maintain it.
FasL has been shown to give similar tolerogenic effects when used for
immunomodulation in other studies

25, 36, 55, 92, 103, 125

. However, other studies

have shown the inability FasL to induce tolerance to allografts 65,

93, 94

.

The

conflicting results may be explained by the difference in function of membrane
and soluble forms, reverse signaling, and its continuous expression when
upregulated through gene therapy68,

92-94, 97, 126-129

.

Complications can arise

especially when FasL is cleaved from the cell membrane by matrix
metalloproteinases and is converted to its soluble form, as the soluble form
causes chemotaxis in neutrophils, competes for binding with membrane-bound
FasL, thereby blocking apoptosis.70, 96, 97.
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In comparison, SA-FasL does not notably increase chemotaxis of
neutrophils, has removed the cleavage site, induces apoptosis in T cells, and is
only transiently displayed on the surface of islets, all of which may lead to the
more consistent results in these studies72,

74, 118

.

For example, islet grafts

ectopically expressing wild type FasL were shown to undergo acute rejection
mediated by neutrophils68,

94

. On top of this, sustained expression may cause

excessive apoptosis which has been shown to result in necroptosis resulting in
inflammatory responses130. Lastly, overexpression of the soluble form of FasL in
tissues rich in metalloproteinases may program an anti-apoptotic and
proinflammatory cascade that results in destructive, rather than protective
immune responses against allografts129.

All in all, the apoptotic SA-FasL

engineered on islet grafts temporarily for localized immunomodulation overcomes
various shortcomings of the wild type FasL.
Induction of tolerance in our model required phagocytes and TGF-β, as
depleting phagocytes or blocking TGF-β resulted in graft rejection. We hypothesize
that Teff cells respond to the islet graft and undergo apoptosis due to the SA-FasL
on the graft. Phagocytes then bind to the apoptotic cells, which causes them to
secrete anti-inflammatory cytokines, including TGF-β, which, in conjunction with
rapamycin, leads to the expansion or conversion of Tregs.

In support of this

hypothesis, confocal microscopy revealed a higher number of macrophages
infiltrating SA-FasL-engineered islet grafts compared to SA-engineered control
grafts soon after transplantation. Some of these macrophages colocalized with
TGF-β in the SA-FasL engineered grafts. TGF- secreted by macrophages or
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other phagocytes binding apoptotic bodies may contribute to the generation and
suppressor function of Treg cells as well as the suppression of T cells within the
grafts

106, 107, 131, 132

. These Tregs may then take up residence within the graft or

home to other sources of inflammation such as a second set of unengineered islets
to establish immune privilege at both sites. Although we demonstrate the direct
role of phagocytes and TGF- in the induction phase of tolerance, the exact
reasons for the necessity of phagocytes and the source of TGF- remain to be
elucidated and will be the subject of future studies.
Despite tolerance being systemic during the induction phase, during the
maintenance phase it is localized to the graft and requires Tregs present and graft
tissue to maintain the immune privilege. Although FasL has been implicated in
acquired immune privilege92,

103, 104

, to our knowledge this is the first study to

provide direct evidence for such a role by demonstrating that a second set of
unmanipulated islet grafts survive rejection following transplantation into the same
site supporting the long-term survival of SA-FasL-engineered islets.

The immune

privilege in our model was antigen-specific and could not be extended to an
unmanipulated islet graft transplanted at a distant site, even in the presence of
rapamycin with the potential to expand and mobilize Treg cells, which are required
for immune privilege in our model. The established immune privilege required the
persistence of alloantigens in the form of the graft, as delayed (4 vs 20 days)
transplantation of the second set of unmanipulated islet graft following the
destruction of original graft with streptozotocin resulted in acute rejection. These
observations are consistent with previous studies on FasL in physiological
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immune privileged sites104, 133. FasL in the eye contained herpes simplex virusinduced inflammation by eliminating activated T cells104.

Corneal grafts

expressing FasL under normal physiological conditions from wild type, but not
mutant mice lacking this molecule, showed long-term survival in allogeneic
recipients103. Our findings are also consistent with studies using tissues with
increased expression of FasL. Syngeneic myoblasts transfected to express FasL
protected unmodified allogenic islets from rejection when co-transplanted under
the same kidney capsule92.
Tolerance was antigen and tissue specific, as SA-FasL-engineered islets
failed to protect third party islet and donor-matched skin and heart grafts. These
observations are consistent with previous studies showing tolerance specificity of
tissue-specific antigens134. However, rejection of donor heart and skin, but not
the third party skin, also resulted in the rejection of SA-FasL-engineered islet
grafts. This may be described by the nature of the immune response to different
tissues. The immune response to skin and heart allografts may elicit a systemic
response which is stronger than the response to islets. SA-FasL-engineered
islets exhibited some tolerance when combined with heart transplantation, as
heart grafts were somewhat prolonged when compared to heart grafts alone.
Skin grafts were not prolonged in the same fashion, which is consistent with
previous studies showing their immunogenicity63. We have previously shown
that transfer of SA-FasL-engineered splenocytes induces tolerance to cardiac
allografts in rats

99

. This study shows that SA-FasL induced tolerance depends

on the nature of the tissue engineered with SA-FasL, treatment dose, and
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setting. In the case of SA-FasL-engineered splenocyte treatment, several
systemic injections of cells were required99.
The transient display of immunomodulatory ligands on the surface of grafts
has the potential to induce permanent graft acceptance in the absence of chronic
immunosuppression. The advantage of a tolerance inducing treatment using SAFasL is antigen specificity that is localized to the graft, which would allow a
competent immune system to fight off infections while leaving the graft as an
immune privileged site.
Immune privilege generated by SA-FasL to islets transplanted with PEG
microgels in chapter 3 also involved Tregs and was localized to the graft. This
was demonstrated by the ability of splenocytes in long-term tolerant mice to
respond normally to donor antigens. These results are consistent with the
established role of FasL in immune privileged tissues, such as the eye and the
testes55,

104, 135

. This is also consistent with a study demonstrating that primary

myoblasts transfected to express FasL conferred immune privilege to cotransplanted allogeneic islet grafts92.
SA-FasL engineering of microgels have several advantages over gene
therapy, including controlled loading, presentation, and retention of SA-FasL in
the graft microenvironment. This is in contrast to gene therapy, which utilizes
uncontrolled, continuous expression of FasL, which possesses multiple functions
and different modes of expression that may be regulated differentially by the
target tissues in membrane bound or soluble form.

SA-FasL presented on

microgels induces localized tolerance without causing major toxicity as compared
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to agonistic Fas antibodies which have been shown to cause toxicity 64. Finally,
SA-FasL-engineered microgels can be prepared and mixed with islets when the
transplantation is to take place, avoiding the multiple manipulations and washing
of islets required by some tolerance protocols. Additional studies in large animal
or humanized mouse models will be necessary for further proof-of-efficacy and
translation to the clinic.
Chapter 3 also showed the use of biomaterial scaffolds in combination
with SA-FasL in order to transplant islets with long-term survival at a site outside
the liver and kidney capsule. This protocol proved to be effective as SA-FasLengineered islet allografts were tolerated and regulated blood glucose for more
than 200 days under a transient cover of rapamycin when transplanted on PLG
scaffolds into an extrahepatic site with translational potential114.
Similar to engineering microgels, engineering SA-FasL on PLG scaffolds
allows for minimal manipulation of islets prior to transplantation.

This would

lessen the damage islets during engineering and washing steps, and as such
may result in better clinical outcomes. As a potential off-the-shelf product, further
studies will be needed to test long-term storage of SA-FasL pre-engineered
scaffolds. Scaffolds were able to be loaded with protein in an enhanced manner
when compared to particles. This is probably due to the higher surface area of
scaffolds. Protein loading and efficiency were similar to other techniques like
carbodiimide coupling to PLG particles136, 137.
Both particles and scaffolds engineered to display SA-FasL were able to
induce apoptosis. Interestingly, for concentrations between 40 and 400 ng/mg,
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the extent of binding was highly consistent within experiments, yet considerable
variation in apoptosis was observed between experiments, suggesting a
sensitivity to the protein loading or presentation within this range. Previous
studies using surface anchored polymer chains with covalently linked agonistic
Fas antibodies were only able to induce up to 34% apoptosis in cells expressing
Fas, while the SA-FasL engineering of biomaterials in our studies was able to
induce 92% apoptosis138. This result may be due to the far greater surface
density of protein (up to 150 ng/cm2 vs 1.6 ng/cm2) and the differences in SAFasL compared to Fas antibody.
Importantly, microporous scaffolds engineered with SA-FasL supported
engraftment and function of the transplanted unmodified allogeneic islets that
maintained normoglycemia for more than 200 days, while islets transplanted on
unmodified PLG scaffolds promptly rejected within 30 days, consistent with our
previous results in subrenal islet transplantation
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. As in the other models, this is

likely due to Tregs in the graft microenvironment. When rapamycin was not
included in the treatment protocol, SA-FasL was able to prolong the graft, which
was also consistent with our findings in the subrenal transplant model74.
In conclusion, engineering allogeneic islets with SA-FasL induces systemic
tolerance during the induction phase, and sustains immune privilege at the graft
site during the maintenance phase. The induction of this immune privilege
requires TGF-β and phagocytes, while maintenance requires Tregs and the graft.
SA-FasL-engineered islets are also able to induce tolerance in when transplanted
in conjunction with PEG microgels or PLG scaffolds. Engineering of both microgels
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and scaffolds also induces tolerance to islet allografts. Utilizing these biomaterials
to lessen the damage to islets and transplant them in new locations may be helpful
in translating SA-FasL based tolerance into the clinic.

Summary, implications, and future directions
In chapter 2, we showed that SA-FasL and rapamycin require TGF-β,
Tregs, and phagocytes to induce tolerance to allogeneic islets. This induction of
tolerance is systemic, as evidenced by protection of a simultaneously transplanted
unmodified allogeneic islet graft under the contralateral kidney capsule. It is antigen
specific, as skin, heart, or third party islet grafts were rejected.
In chapter 3 we showed that SA-FasL-engineered PEG-4MAL microgels in
conjunction with a short course of rapamycin were effective at inducing long-term
tolerance to cotransplanted allogeneic islets in a BALB/c-to-C57BL/6 mouse model
of diabetes. Long-term tolerance was not achieved without rapamycin, although
rejection was significantly delayed when microgels and islets were both engineered
with SA-FasL in the same model. This tolerance also required Tregs as their
depletion by diphtheria toxin resulted in prompt graft rejection. We also showed the
effectiveness of microporous PLG scaffolds loaded with SA-FasL-islets and
transplanted in the EFP to induce long-term tolerance in this model when
accompanied with a short course of rapamycin administration. SA-FasL-engineered
scaffolds and rapamycin were also effective at inducing long-term tolerance to
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loaded islets. Engineering both the scaffolds and loaded islets induced long-term
tolerance in one third of the mice in the absence of rapamycin.
In all of these studies, maintenance of tolerance was localized to the graft,
as splenic T cells from long-term tolerant mice proliferated in a manner similar to
control splenocytes when stimulated with allogeneic splenocytes. This indicates
that, if translated into the clinic, a treatment using SA-FasL-engineered islets or
biomaterials would have little effect on graft recipients’ overall immune system,
reducing their risk of infections and malignancies compared to graft recipients on
chronic immunosuppressive drugs. In addition, such a treatment would reduce the
damage to kidney, liver, and islets present in current clinical transplant recipients
due to the toxicity of immunosuppressives.
As a substitute for the murine epididymal fat pad, the omentum could be
used in future clinical trials. Indeed, islet transplants have been done on the
omentum utilizing scaffolds in nonhuman primates and humans 139, 140. Before
clinical trials can commence utilizing SA-FasL-engineered PLG scaffolds loaded
with islets, we may first test the viability using a humanized mouse model.
Additionally, since SA-FasL is derived from rat FasL, we will first start by creating
chimeric human SA-FasL and testing it in humanized mouse models of islet
transplantation.
Additionally, we must also consider the difference in mouse versus human
immunity in other aspects. As humans come in contact with more organisms which
can generate inflammation in transplant recipients, and also because of higher
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levels of preexisting memory T cells (heterologous immunity)57, 58 as compared to
clean laboratory mice, more stringent tolerance protocols must be utilized for
clinical trials. Such protocols could simply include additional immunosuppressive
drugs currently used for intraportal transplants, daclizumab and tacrolimus.
However, there may not be a need to use them long-term if SA-FasL is effective at
inducing apoptosis of graft specific T cells and inducing Tregs which take up
residence within the graft as seen in the mouse transplant model.
Further studies will investigate injection of soluble SA-FasL. While soluble
FasL was shown to cause chemotaxis of neutrophils and inflammation68, SA-FasL
forms tetramers and oligomers, and can cause apoptosis in vitro. Soluble SA-FasL
injection is a simple addition to our protocol as it does not require incubation steps.
Indeed, if soluble SA-FasL were used in place of engineering, less islets would be
lost due to washing and time spent in media. On top of this, soluble SA-FasL would
be easy to modify dosage timing and amounts. However, soluble SA-FasL would
likely influence the systemic immune system.
Finally, we will explore other chimeric proteins with potential for influencing
tolerance, such as SA-IL-2 or SA-TGF-β. These two may specifically attract or
generate Tregs at the site of the transplant. In addition to its ability to generate
Tregs, membrane bound TGF-β on Tregs was shown to be protective against
diabetes in NOD mice141. Therefore, we may look into Treg therapies using SATGF-β.
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